Jim Cramer's Latest Post

We're Still in the Tech W...

More Trading Strategies

By

Brian Sozzi

 | Apr 21, 2014 | 10:30 AM EDT |
Spotty earnings give retail investors little reason to buy at these valuations.
By

James "Rev Shark" DePorre

 | Apr 21, 2014 | 10:24 AM EDT |
Speculative names are attracting some attention.
By

Toni Hansen

 | Apr 21, 2014 | 9:30 AM EDT |
 But it may be susceptible to another daily to weekly pullback,
By

Jim Cramer

 | Apr 21, 2014 | 8:37 AM EDT |
When people attach such frothy numbers to IPOs, we have problems.
By

Paul Curcio

 | Apr 21, 2014 | 8:31 AM EDT |
Futures point higher; AstraZeneca rises on bid talk.
By

Bob Byrne

 | Apr 21, 2014 | 7:00 AM EDT |
The SPY is back inside its $184-to-$189 balance zone.
By

Christopher Versace

 | Apr 20, 2014 | 8:00 PM EDT |
Here are some questions to ask as the numbers roll in.
By

Helene Meisler

 | Apr 20, 2014 | 7:00 PM EDT |
Keep your eyes open this week.
By

Carolyn Boroden

 | Apr 20, 2014 | 6:00 PM EDT |
These parameters should help you out.
By

Robert Lang

 | Apr 20, 2014 | 10:30 AM EDT |
And don't waste your time on a plethora of conflicting views.
By

John Reese

 | Apr 19, 2014 | 10:30 AM EDT |
My guru strategy is quite impressed with these slot-machine makers
By

Jim Cramer

 | Apr 17, 2014 | 7:14 PM EDT |
Maybe we can get some perspective about stocks that were loved.
By

Daniel Dicker

 | Apr 17, 2014 | 3:50 PM EDT |
Now is the time to position and hold in natural gas names.
By

James "Rev Shark" DePorre

 | Apr 17, 2014 | 3:47 PM EDT |
Let's see if today's forgiving market mood continues next week.
By

Timothy Collins

 | Apr 17, 2014 | 3:19 PM EDT |
Low volatility ahead of a long weekend creates good conditions.

Upgrades & Downgrades

Apr 21, 2014 | 8:34 AM EDT
PCRX was initiated with a Buy rating, BAML said. Driven by upside in analgesic Exparel. $86 price target. 
Apr 21, 2014 | 8:30 AM EDT
UFPI was upgraded to Buy from Neutral, DA Davidson said. Overreaction to missed earnings, co set to perform well rest of 2014. $53 pric…
Update
Apr 21, 2014 | 8:25 AM EDT
PDC was downgraded to Market Perform from Outperform, BMO said. Valuation call. $63 price target.
Apr 21, 2014 | 8:21 AM EDT
AGTC initiated with an Outperform rating, BMO said. Supported by best in class gene therapy platform and several opportunities focused …
Update
Apr 21, 2014 | 8:10 AM EDT
DYN was upgraded to Buy from Neutral, UBS said. Driven by latest commodity rally. $31 price target. 
Some pretty heavy SPY call volume hit at the open on the May 192 call strike, 20K contract...
Last week's sell-off in Big Blue appears to have run its course. As of 10:03 AM IBM was up...
When asked about the difference between genius and stupidity Mr. Einstein answered, "Geniu...
Many markets are closed today following Easter, these include: Australia, France, Germany,...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.